Published Technical Disclosure Archive

Synergistic Zika Virus Vaccine and Surveillance System

Publication ID: 24-11857616_0008_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Zika Virus Vaccine and Surveillance System,” Published Technical Disclosure No. 24-11857616_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857616_0008_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,616.

Summary of the Inventive Concept

A novel system integrating a recombinant measles virus expressing Zika virus prM and E proteins with AI, IoT, blockchain, and advanced materials to enhance vaccine efficacy, track outbreaks, and enable personalized vaccine development.

Background and Problem Solved

The original patent for a recombinant measles virus expressing Zika virus prM and E proteins addressed the need for an effective Zika virus vaccine. However, the patent's limitations include the lack of integration with advanced technologies to enhance vaccine efficacy, track outbreaks, and enable personalized vaccine development. The new inventive concept addresses these limitations by combining the recombinant measles virus with AI, IoT, blockchain, and advanced materials.

Detailed Description of the Inventive Concept

The synergistic system comprises a recombinant measles virus expressing Zika virus prM and E proteins, which serves as a vaccine candidate. The system integrates an artificial intelligence module to optimize vaccine efficacy based on genomic analysis of Zika virus strains. Additionally, the system includes a blockchain-based platform integrated with IoT sensors for tracking Zika virus outbreaks and a graphene-based nanoparticle for enhanced vaccine delivery and efficacy. Furthermore, the system incorporates a machine learning algorithm for predicting individual immune responses to different Zika virus strains, enabling personalized vaccine development. The system also features a real-time monitoring method using IoT-enabled sensors and a blockchain-based data storage system.

Novelty and Inventive Step

The new inventive concept is novel and non-obvious due to the synergistic combination of the recombinant measles virus with AI, IoT, blockchain, and advanced materials, which provides a more effective and comprehensive approach to Zika virus vaccine development and surveillance.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different AI algorithms, IoT sensor configurations, or blockchain platforms. Additionally, the system could be adapted for use with other viruses or diseases, or integrated with other advanced technologies such as CRISPR gene editing or synthetic biology.

Potential Commercial Applications and Market

The synergistic Zika virus vaccine and surveillance system has significant commercial potential in the vaccine development and public health surveillance markets. The system's ability to enhance vaccine efficacy, track outbreaks, and enable personalized vaccine development addresses a critical need in the global healthcare industry.

CPC Classifications

SectionClassGroup
A A61 A61K39/12
C C07 C07K14/005
C C12 C12N7/00
A A61 A61K2039/5254
A A61 A61K2039/53
C C12 C12N2760/18421
C C12 C12N2760/18423
C C12 C12N2770/24122
C C12 C12N2770/24123
C C12 C12N2770/24134

Field of Art

Virology, vaccine development, recombinant viral vector technologies, with expertise in molecular biology, immunology, and genetic engineering of viral vectors

Person of Ordinary Skill (PHOSITA) Profile

A skilled researcher with a PhD in virology or molecular biology, familiar with recombinant virus techniques, vaccine design, and emerging technologies for disease surveillance and personalized medicine

Obviousness Rationale

A PHOSITA would recognize that integrating advanced technologies like AI, blockchain, and nanomaterials with the existing recombinant measles virus Zika vaccine platform represents a predictable extension of known vaccine development strategies. The core viral vector technology from the source patent provides a foundational platform that naturally invites optimization through emerging digital and materials technologies. These combinations represent logical incremental improvements that would be apparent to a skilled researcher seeking to enhance vaccine efficacy and deployment.

Obvious Combinations & Variations

Source Patent Element
Recombinant measles virus expressing Zika virus prM and E proteins
PTD Variation
Adding AI-driven genomic analysis for vaccine optimization
Obviousness Reasoning
Using machine learning to analyze viral genomic variations is a known technique in vaccine development, representing a predictable application of computational methods to improve vaccine design
Source Patent Element
Nucleic acid construct for viral protein expression
PTD Variation
Incorporating graphene-based nanoparticles for enhanced vaccine delivery
Obviousness Reasoning
Advanced drug delivery technologies are routinely explored to improve vaccine efficacy, and nanomaterial integration represents a standard approach for enhancing antigen presentation and immune response
Source Patent Element
Live-attenuated measles virus vaccine strain
PTD Variation
Blockchain and IoT-enabled outbreak tracking and surveillance system
Obviousness Reasoning
Digital technologies for disease monitoring are increasingly common, and integrating advanced tracking mechanisms with existing vaccine platforms represents a logical and predictable technological progression
Source Patent Element
Codon-optimized polynucleotide for protein expression
PTD Variation
Machine learning algorithm for predicting individual immune responses
Obviousness Reasoning
Personalized medicine approaches using computational prediction are emerging standard techniques in vaccine development, representing an obvious extension of existing genetic and immunological research
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857616 and the disclosed technological variations, a person of ordinary skill in the art would find the proposed combinations of recombinant viral vector technology with AI, blockchain, IoT, and advanced materials to be obvious extensions of the prior art, lacking the requisite non-obviousness for patent protection under 35 U.S.C. ยง 103.

Original Patent Information

Patent NumberUS 11,857,616
TitleRecombinant measles virus expressing zika virus prM and E proteins
Assignee(s)CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Institut Pasteur